Activery The amorphization specialist
Activery believes that amorphous drugs provide new and innovative routes to final dosage forms with differentiated pharmacokinetics
| Early generics |
 |
 |
 |
Gaining your right to be the firstGeneric entry of a drug is often delayed due to patents claiming additional crystalline forms. In contrast, an amorphous form would allow generic entry at the date of the molecule patent expiry. Additionally, amorphous particles will dissolve better in biological fluids leading to potentially higher bioavailability, overcoming high-throughput screening issues which preferentially produce highly water insoluble lead candidates. However, an amorphous form is usually not pursued citing risk avoidance strategies and inherent physical and chemical problems with amorphous solids. Activery speeds generic entranceActivery produces physically and chemically stable drug-excipient composites which can be used for further formulation into a finished dosage form. Together with our clients we are identifying molecule opportunities for early generic market entry of a bioequivalent form or a product with improved physiological properties. Our unique knowledge of amorphous solids and their formulation promises a high success rate to be the ‘first-to-file'. Development expertise from the amorphization specialist
|
Pharma Notes
- New study on Inhaled Drug Delivery Market
- Particles that deliver larger and more effective doses of drugs to cancers
- The global protein therapeutics market will be worth $77bn by 2011 with biogenerics playing an increasingly important rol
- A federal jury in Texas Monday upheld the patent on Johnson & Johnson's arthritis treatment Remicade and ordered Abbott Laboratories to pay its rival $1.67 billion for infringing on the patent
- Transdermal delivery represents an attractive alternative to oral delivery of drugs and is poised to provide an alternative to hypodermic injection tool
Differentiated Generics
- Teva may lose patent challenge
- Labopharm receives notice of ANDA submission with paragraph IV certification for generic of Ryzolt
- Depomed (DEPO) Receives Paragraph IV Notice from Lupin Limited Over Patent Filing for Generic Glumetza Tablets
- The rate and number of successful Paragraph IV challenges is reducing the average effective patent life for innovator drugs
- Teva Sues Mylan Over Multiple Sclerosis Drug COPAXONE
Nanoparticles world
- Nanoparticle created to attack cardiovascular plaque
- Nanoparticle lung threat blocked
- Newly-developed nanoparticle to build therapies for treating individuals with cardiovascular disease.
- Nanoparticle Processing in the Solid State Dramatically Increases the Cell Membrane Permeation of a Cholesterol-Lowering Drug, Probucol
- Erectile dysfunction could be treated by a nanoparticle formulation applied directly to the penis